LXRX
Lexicon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.24
−0.88%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.6x
Market Cap
$996.70M
MomentumView details →
1D Return
−0.88%
YTD Return
+94.32%
RSI (14)
45.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−16.6x
Market Cap
$996.70M
RSI (14)
45.3
MomentumView details →
1D Return
−0.88%
YTD Return
+94.32%
SummaryUpdated Jun 1, 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company founded in 1995 and headquartered in The Woodlands, Texas. The company went public in 2000 and focuses on discovering, developing, and commercializing small molecule pharmaceutical products primarily for cardiovascular, metabolic, and neurological conditions. Lexicon has evolved from a drug discovery company into a commercial-stage biopharmaceutical company with one approved product and multiple late-stage pipeline candidates targeting significant unmet medical needs.
Similar companies
Latest newsMore news →
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.12d agoLexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial.29d ago